dr. postow on fda approval of adjuvant dabrafenib plus trametinib in braf-mutant melanoma
Published 6 years ago • 162 plays • Length 0:30Download video MP4
Download video MP3
Similar videos
-
1:11
dr. weber on the fda approval of adjuvant dabrafenib/trametinib in braf-mutant melanoma
-
1:08
fda approval of adjuvant dabrafenib/trametinib in braf melanoma
-
0:18
copy of dr. weber on the fda approval of adjuvant dabrafenib/trametinib in braf-mutant melanoma
-
2:16
dr. rodabe n. amaria on dabrafenib plus trametinib in melanoma
-
1:31
dr. daud on dabrafenib/trametinib vs immunotherapy in melanoma
-
2:33
dr. sullivan discusses role of dabrafenib plus trametinib in melanoma
-
7:03
2020 melanoma - postow - what is the correct choice for first line therapy for braf melanoma
-
1:04
dr. wilson on long-term data with dabrafenib plus trametinib in melanoma
-
2:19
dr. robert on 5-year analysis of dabrafenib/trametinib in braf v600-mutant melanoma
-
1:08
dr. weber on dabrafenib/trametinib versus vemurafenib/cobimetinib in melanoma
-
1:26
dr. nathan on long-term outcomes with dabrafenib/trametinib in braf v600-mutant melanoma
-
4:12
adjuvant therapy in melanoma: combi-ad trial
-
0:57
dr. postow discusses side effects with combinations in melanoma
-
1:49
dr. luke on the fda approval of adjuvant nivolumab in melanoma
-
2:51
combi-ad: long-term follow-up of dabrafenib and trametinib in braf-mutated melanoma
-
1:46
dr. nathan on 5-year survival outcomes of combi-d and combi-v trials in braf v600-mutant melanoma
-
0:59
the success of the dabrafenib and trametinib combination in braf-mutated melanoma
-
1:17
dr. postow discusses combination therapy for melanoma
-
1:17
dr. postow on combination regimens for high-risk melanoma